Dapa Met Xr 5/1000 Mg Tablet – Extended-Release Dual Therapy for Type 2 Diabetes
Dapa Met Xr 5/1000 Mg Tablet – Extended-Release Dual Therapy for Type 2 Diabetes
Dapa Met Xr 5/1000 Mg Tablet – Extended-Release Dual Therapy for Type 2 Diabetes
Description
Dapa Met Xr 5/1000 Mg Tablet – 24-Hour Glycemic Control with Heart & Kidney Protection
Dapa Met Xr 5/1000 Mg Tablet combines dapagliflozin 5 mg (SGLT2 inhibitor) with metformin 1000 mg in an advanced extended-release formulation to deliver steady, all-day blood sugar management for adults with type 2 diabetes. Dapagliflozin removes excess glucose through urine while the slow-release metformin reduces liver glucose output and improves insulin sensitivity with minimal gastrointestinal discomfort. This once-daily tablet is ideal for patients needing stronger metformin dosing alongside proven cardiovascular and renal protective benefits, offering significant HbA1c reduction, modest weight loss, and low risk of hypoglycemia when used with diet and exercise under medical supervision.
